Skip to main content
NCBI home page
Journal of the Royal Society of Medicine logoLink to Journal of the Royal Society of Medicine
. 1993;86(Suppl 20):11–18.

Microbiology of cystic fibrosis lung infections: themes and issues.

J R Govan 1, J W Nelson 1
PMCID: PMC1293798  PMID: 7684788

Full text

PDF
11

Images in this article

11Figure 1.
on p.11

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson T. R., Montie T. C., Murphy M. D., McCarthy V. P. Pseudomonas aeruginosa flagellar antibodies in patients with cystic fibrosis. J Clin Microbiol. 1989 Dec;27(12):2789–2793. doi: 10.1128/jcm.27.12.2789-2793.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aronoff S. C., Quinn F. J., Jr, Stern R. C. Longitudinal serum IgG response to Pseudomonas cepacia surface antigens in cystic fibrosis. Pediatr Pulmonol. 1991;11(4):289–293. doi: 10.1002/ppul.1950110404. [DOI] [PubMed] [Google Scholar]
  3. Aronoff S. C., Stern R. C. Serum IgG antibody to outer membrane antigens of Pseudomonas cepacia and Pseudomonas aeruginosa in cystic fibrosis. J Infect Dis. 1988 May;157(5):934–940. doi: 10.1093/infdis/157.5.934. [DOI] [PubMed] [Google Scholar]
  4. Baltimore R. S., Christie C. D., Smith G. J. Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration. Am Rev Respir Dis. 1989 Dec;140(6):1650–1661. doi: 10.1164/ajrccm/140.6.1650. [DOI] [PubMed] [Google Scholar]
  5. Beckman W., Lessie T. G. Response of Pseudomonas cepacia to beta-Lactam antibiotics: utilization of penicillin G as the carbon source. J Bacteriol. 1979 Dec;140(3):1126–1128. doi: 10.1128/jb.140.3.1126-1128.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brett M. M., Ghoneim A. T., Littlewood J. M., Losowsky M. S. Development of enzyme linked immunosorbent assay (ELISA) to detect antibodies to Pseudomonas aeruginosa cell surface antigens in sera of patients with cystic fibrosis. J Clin Pathol. 1986 Oct;39(10):1124–1129. doi: 10.1136/jcp.39.10.1124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Brett M. M., Ghoneim A. T., Littlewood J. M. Prediction and diagnosis of early Pseudomonas aeruginosa infection in cystic fibrosis: a follow-up study. J Clin Microbiol. 1988 Aug;26(8):1565–1570. doi: 10.1128/jcm.26.8.1565-1570.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Brett M. M., Ghoneim A. T., Littlewood J. M. Serum IgA antibodies against Pseudomonas aeruginosa in cystic fibrosis. Arch Dis Child. 1990 Mar;65(3):259–263. doi: 10.1136/adc.65.3.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cordon S. M., Elborn J. S., Rayner R. J., Hiller E. J., Shale D. J. IgG antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis. Arch Dis Child. 1992 Jun;67(6):737–740. doi: 10.1136/adc.67.6.737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cukor G., Blacklow N. R., Nowak N. A., Rich C. M., Braverman L. E., Fischer R. A. Comparative analysis of serum antibody responses to Pseudomonas aeruginosa exotoxin A by cystic fibrosis and intensive care unit patients. J Clin Microbiol. 1983 Sep;18(3):457–462. doi: 10.1128/jcm.18.3.457-462.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dasgupta M. K., Lam J., Döring G., Harley F. L., Zuberbuhler P., Lam K., Reichert A., Costerton J. W., Dossetor J. B. Prognostic implications of circulating immune complexes and Pseudomonas aeruginosa-specific antibodies in cystic fibrosis. J Clin Lab Immunol. 1987 May;23(1):25–30. [PubMed] [Google Scholar]
  12. Deretic V., Mohr C. D., Martin D. W. Mucoid Pseudomonas aeruginosa in cystic fibrosis: signal transduction and histone-like elements in the regulation of bacterial virulence. Mol Microbiol. 1991 Jul;5(7):1577–1583. doi: 10.1111/j.1365-2958.1991.tb01903.x. [DOI] [PubMed] [Google Scholar]
  13. Dorin J. R., Dickinson P., Alton E. W., Smith S. N., Geddes D. M., Stevenson B. J., Kimber W. L., Fleming S., Clarke A. R., Hooper M. L. Cystic fibrosis in the mouse by targeted insertional mutagenesis. Nature. 1992 Sep 17;359(6392):211–215. doi: 10.1038/359211a0. [DOI] [PubMed] [Google Scholar]
  14. Döring G., Goldstein W., Röll A., Schiøtz P. O., Høiby N., Botzenhart K. Role of Pseudomonas aeruginosa exoenzymes in lung infections of patients with cystic fibrosis. Infect Immun. 1985 Sep;49(3):557–562. doi: 10.1128/iai.49.3.557-562.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Döring G., Høiby N. Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect Immun. 1983 Oct;42(1):197–201. doi: 10.1128/iai.42.1.197-201.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Finlay B. B., Falkow S. Common themes in microbial pathogenicity. Microbiol Rev. 1989 Jun;53(2):210–230. doi: 10.1128/mr.53.2.210-230.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fomsgaard A., Høiby N., Shand G. H., Conrad R. S., Galanos C. Longitudinal study of antibody response to lipopolysaccharides during chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. Infect Immun. 1988 Sep;56(9):2270–2278. doi: 10.1128/iai.56.9.2270-2278.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Geers T. A., Baker N. R. The effect of sublethal levels of antibiotics on the pathogenicity of Pseudomonas aeruginosa for tracheal tissue. J Antimicrob Chemother. 1987 May;19(5):569–578. doi: 10.1093/jac/19.5.569. [DOI] [PubMed] [Google Scholar]
  19. Gessner A. R., Mortensen J. E. Pathogenic factors of Pseudomonas cepacia isolates from patients with cystic fibrosis. J Med Microbiol. 1990 Oct;33(2):115–120. doi: 10.1099/00222615-33-2-115. [DOI] [PubMed] [Google Scholar]
  20. Gilligan P. H. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev. 1991 Jan;4(1):35–51. doi: 10.1128/cmr.4.1.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Gladman G., Connor P. J., Williams R. F., David T. J. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis. Arch Dis Child. 1992 Feb;67(2):192–195. doi: 10.1136/adc.67.2.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Glass S., Hayward C., Govan J. R. Serum C-reactive protein in assessment of pulmonary exacerbations and antimicrobial therapy in cystic fibrosis. J Pediatr. 1988 Jul;113(1 Pt 1):76–79. doi: 10.1016/s0022-3476(88)80533-x. [DOI] [PubMed] [Google Scholar]
  23. Govan J. R., Doherty C., Glass S. Rational parameters for antibiotic therapy in patients with cystic fibrosis. Infection. 1987 Jul-Aug;15(4):300–307. doi: 10.1007/BF01644142. [DOI] [PubMed] [Google Scholar]
  24. Govan J. R., Fyfe J. A. Mucoid Pseudomonas aeruginosa and cystic fibrosis: resistance of the mucoid from to carbenicillin, flucloxacillin and tobramycin and the isolation of mucoid variants in vitro. J Antimicrob Chemother. 1978 May;4(3):233–240. doi: 10.1093/jac/4.3.233. [DOI] [PubMed] [Google Scholar]
  25. Govan J. R., Nelson J. W. Microbiology of lung infection in cystic fibrosis. Br Med Bull. 1992 Oct;48(4):912–930. doi: 10.1093/oxfordjournals.bmb.a072585. [DOI] [PubMed] [Google Scholar]
  26. Hancock R. E., Mouat E. C., Speert D. P. Quantitation and identification of antibodies to outer-membrane proteins of Pseudomonas aeruginosa in sera of patients with cystic fibrosis. J Infect Dis. 1984 Feb;149(2):220–226. doi: 10.1093/infdis/149.2.220. [DOI] [PubMed] [Google Scholar]
  27. Hollsing A. E., Granström M., Vasil M. L., Wretlind B., Strandvik B. Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis. J Clin Microbiol. 1987 Oct;25(10):1868–1874. doi: 10.1128/jcm.25.10.1868-1874.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Høiby N., Döring G., Schiøtz P. O. The role of immune complexes in the pathogenesis of bacterial infections. Annu Rev Microbiol. 1986;40:29–53. doi: 10.1146/annurev.mi.40.100186.000333. [DOI] [PubMed] [Google Scholar]
  29. Høiby N., Koch C. Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax. 1990 Nov;45(11):881–884. doi: 10.1136/thx.45.11.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Isles A., Maclusky I., Corey M., Gold R., Prober C., Fleming P., Levison H. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr. 1984 Feb;104(2):206–210. doi: 10.1016/s0022-3476(84)80993-2. [DOI] [PubMed] [Google Scholar]
  31. Jeffery P. K., Brain A. P. Surface morphology of human airway mucosa: normal, carcinoma or cystic fibrosis. Scanning Microsc. 1988 Mar;2(1):553–560. [PubMed] [Google Scholar]
  32. Langford D. T., Hiller J. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results. Arch Dis Child. 1984 Dec;59(12):1131–1134. doi: 10.1136/adc.59.12.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. LiPuma J. J., Dasen S. E., Nielson D. W., Stern R. C., Stull T. L. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet. 1990 Nov 3;336(8723):1094–1096. doi: 10.1016/0140-6736(90)92571-x. [DOI] [PubMed] [Google Scholar]
  34. Littlewood J. M., Miller M. G., Ghoneim A. T., Ramsden C. H. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet. 1985 Apr 13;1(8433):865–865. doi: 10.1016/s0140-6736(85)92222-6. [DOI] [PubMed] [Google Scholar]
  35. Lonon M. K., Woods D. E., Straus D. C. Production of lipase by clinical isolates of Pseudomonas cepacia. J Clin Microbiol. 1988 May;26(5):979–984. doi: 10.1128/jcm.26.5.979-984.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Moss R. B., Lewiston N. J. Immune complexes and humoral response to Pseudomonas aeruginosa in cystic fibrosis. Am Rev Respir Dis. 1980 Jan;121(1):23–29. doi: 10.1164/arrd.1980.121.1.23. [DOI] [PubMed] [Google Scholar]
  37. Nelson J. W., Doherty C. J., Brown P. H., Greening A. P., Kaufmann M. E., Govan J. R. Pseudomonas cepacia in inpatients with cystic fibrosis. Lancet. 1991 Dec 14;338(8781):1525–1525. doi: 10.1016/0140-6736(91)92342-y. [DOI] [PubMed] [Google Scholar]
  38. Nelson J. W., Tredgett M. W., Sheehan J. K., Thornton D. J., Notman D., Govan J. R. Mucinophilic and chemotactic properties of Pseudomonas aeruginosa in relation to pulmonary colonization in cystic fibrosis. Infect Immun. 1990 Jun;58(6):1489–1495. doi: 10.1128/iai.58.6.1489-1495.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Pedersen S. S., Espersen F., Høiby N. Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay. J Clin Microbiol. 1987 Oct;25(10):1830–1836. doi: 10.1128/jcm.25.10.1830-1836.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Pedersen S. S., Høiby N., Shand G. H., Pressler T. Antibody response to Pseudomonas aeruginosa antigens in cystic fibrosis. Antibiot Chemother (1971) 1989;42:130–153. doi: 10.1159/000417614. [DOI] [PubMed] [Google Scholar]
  41. Pier G. B., Meluleni G., Neuger E. A murine model of chronic mucosal colonization by Pseudomonas aeruginosa. Infect Immun. 1992 Nov;60(11):4768–4776. doi: 10.1128/iai.60.11.4768-4776.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Pier G. B., Saunders J. M., Ames P., Edwards M. S., Auerbach H., Goldfarb J., Speert D. P., Hurwitch S. Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis. N Engl J Med. 1987 Sep 24;317(13):793–798. doi: 10.1056/NEJM198709243171303. [DOI] [PubMed] [Google Scholar]
  43. Pier G. B., Small G. J., Warren H. B. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections. Science. 1990 Aug 3;249(4968):537–540. doi: 10.1126/science.2116663. [DOI] [PubMed] [Google Scholar]
  44. Plotkowski M. C., Chevillard M., Pierrot D., Altemayer D., Zahm J. M., Colliot G., Puchelle E. Differential adhesion of Pseudomonas aeruginosa to human respiratory epithelial cells in primary culture. J Clin Invest. 1991 Jun;87(6):2018–2028. doi: 10.1172/JCI115231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Przyklenk B., Bauernfeind A. Significance of immunologic factors in cystic fibrosis. Scand J Gastroenterol Suppl. 1988;143:103–109. doi: 10.3109/00365528809090227. [DOI] [PubMed] [Google Scholar]
  46. Ramphal R., Carnoy C., Fievre S., Michalski J. C., Houdret N., Lamblin G., Strecker G., Roussel P. Pseudomonas aeruginosa recognizes carbohydrate chains containing type 1 (Gal beta 1-3GlcNAc) or type 2 (Gal beta 1-4GlcNAc) disaccharide units. Infect Immun. 1991 Feb;59(2):700–704. doi: 10.1128/iai.59.2.700-704.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Ramphal R., Guay C., Pier G. B. Pseudomonas aeruginosa adhesins for tracheobronchial mucin. Infect Immun. 1987 Mar;55(3):600–603. doi: 10.1128/iai.55.3.600-603.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Ramphal R. The role of bacterial adhesion in cystic fibrosis including the staphylococcal aspect. Infection. 1990 Jan-Feb;18(1):61–64. doi: 10.1007/BF01644188. [DOI] [PubMed] [Google Scholar]
  49. Rayner R. J., Wiseman M. S., Cordon S. M., Norman D., Hiller E. J., Shale D. J. Inflammatory markers in cystic fibrosis. Respir Med. 1991 Mar;85(2):139–145. doi: 10.1016/s0954-6111(06)80292-1. [DOI] [PubMed] [Google Scholar]
  50. Reddy M. S. Human tracheobronchial mucin: purification and binding to Pseudomonas aeruginosa. Infect Immun. 1992 Apr;60(4):1530–1535. doi: 10.1128/iai.60.4.1530-1535.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Sajjan U. S., Corey M., Karmali M. A., Forstner J. F. Binding of Pseudomonas cepacia to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis. J Clin Invest. 1992 Feb;89(2):648–656. doi: 10.1172/JCI115631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Schaad U. B., Lang A. B., Wedgwood J., Ruedeberg A., Que J. U., Fürer E., Cryz S. J., Jr Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet. 1991 Nov 16;338(8777):1236–1237. doi: 10.1016/0140-6736(91)92103-9. [DOI] [PubMed] [Google Scholar]
  53. Schiøtz P. O., Høiby N., Permin H., Wiik A. IgA and IgG antibodies against surface antigens of Pseudomonas aeruginosa in sputum and serum from patients with cystic fibrosis. Acta Pathol Microbiol Scand C. 1979 Jun;87C(3):229–233. [PubMed] [Google Scholar]
  54. Shand G. H., Pedersen S. S., Lam K., Høiby N. Iron-regulated outer membrane proteins and virulence in Pseudomonas aeruginosa. Antibiot Chemother (1971) 1989;42:15–26. doi: 10.1159/000417599. [DOI] [PubMed] [Google Scholar]
  55. Shand G. H., Pedersen S. S., Tilling R., Brown M. R., Høiby N. Use of immunoblot detection of serum antibodies in the diagnosis of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. J Med Microbiol. 1988 Nov;27(3):169–177. doi: 10.1099/00222615-27-3-169. [DOI] [PubMed] [Google Scholar]
  56. Simmonds E. J., Conway S. P., Ghoneim A. T., Ross H., Littlewood J. M. Pseudomonas cepacia: a new pathogen in patients with cystic fibrosis referred to a large centre in the United Kingdom. Arch Dis Child. 1990 Aug;65(8):874–877. doi: 10.1136/adc.65.8.874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Smith D. L., Smith E. G., Gumery L. B., Stableforth D. E. Pseudomonas cepacia infection in cystic fibrosis. Lancet. 1992 Jan 25;339(8787):252–252. doi: 10.1016/0140-6736(92)90063-9. [DOI] [PubMed] [Google Scholar]
  58. Straus D. C., Woods D. E., Lonon M. K., Garner C. W. The importance of extracellular antigens in Pseudomonas cepacia infections. J Med Microbiol. 1988 Aug;26(4):269–280. doi: 10.1099/00222615-26-4-269. [DOI] [PubMed] [Google Scholar]
  59. Tablan O. C., Carson L. A., Cusick L. B., Bland L. A., Martone W. J., Jarvis W. R. Laboratory proficiency test results on use of selective media for isolating Pseudomonas cepacia from simulated sputum specimens of patients with cystic fibrosis. J Clin Microbiol. 1987 Mar;25(3):485–487. doi: 10.1128/jcm.25.3.485-487.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Tablan O. C., Martone W. J., Doershuk C. F., Stern R. C., Thomassen M. J., Klinger J. D., White J. W., Carson L. A., Jarvis W. R. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes. Chest. 1987 Apr;91(4):527–532. doi: 10.1378/chest.91.4.527. [DOI] [PubMed] [Google Scholar]
  61. Taylor R. F., Gaya H., Hodson M. E. Temocillin and cystic fibrosis: outcome of intravenous administration in patients infected with Pseudomonas cepacia. J Antimicrob Chemother. 1992 Mar;29(3):341–344. doi: 10.1093/jac/29.3.341. [DOI] [PubMed] [Google Scholar]
  62. Thomassen M. J., Demko C. A., Klinger J. D., Stern R. C. Pseudomonas cepacia colonization among patients with cystic fibrosis. A new opportunist. Am Rev Respir Dis. 1985 May;131(5):791–796. doi: 10.1164/arrd.1985.131.5.791. [DOI] [PubMed] [Google Scholar]
  63. Tsang V., Hodson M. E., Yacoub M. H. Lung transplantation for cystic fibrosis. Br Med Bull. 1992 Oct;48(4):949–971. doi: 10.1093/oxfordjournals.bmb.a072587. [DOI] [PubMed] [Google Scholar]
  64. Valerius N. H., Koch C., Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991 Sep 21;338(8769):725–726. doi: 10.1016/0140-6736(91)91446-2. [DOI] [PubMed] [Google Scholar]
  65. Vasil M. L., Krieg D. P., Kuhns J. S., Ogle J. W., Shortridge V. D., Ostroff R. M., Vasil A. I. Molecular analysis of hemolytic and phospholipase C activities of Pseudomonas cepacia. Infect Immun. 1990 Dec;58(12):4020–4029. doi: 10.1128/iai.58.12.4020-4029.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Vishwanath S., Guay C. M., Ramphal R. Effects of subminimal inhibitory concentrations of antibiotics on the adherence of Pseudomonas aeruginosa to tracheobronchial mucin. J Antimicrob Chemother. 1987 May;19(5):579–583. doi: 10.1093/jac/19.5.579. [DOI] [PubMed] [Google Scholar]
  67. Vishwanath S., Ramphal R. Adherence of Pseudomonas aeruginosa to human tracheobronchial mucin. Infect Immun. 1984 Jul;45(1):197–202. doi: 10.1128/iai.45.1.197-202.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Vishwanath S., Ramphal R. Tracheobronchial mucin receptor for Pseudomonas aeruginosa: predominance of amino sugars in binding sites. Infect Immun. 1985 May;48(2):331–335. doi: 10.1128/iai.48.2.331-335.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Warner J. O. Immunology of cystic fibrosis. Br Med Bull. 1992 Oct;48(4):893–911. doi: 10.1093/oxfordjournals.bmb.a072584. [DOI] [PubMed] [Google Scholar]
  70. Wheeler W. B., Williams M., Matthews W. J., Jr, Colten H. R. Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study. J Pediatr. 1984 May;104(5):695–699. doi: 10.1016/s0022-3476(84)80946-4. [DOI] [PubMed] [Google Scholar]
  71. Woods D. E., Straus D. C., Johanson W. G., Jr, Berry V. K., Bass J. A. Role of pili in adherence of Pseudomonas aeruginosa to mammalian buccal epithelial cells. Infect Immun. 1980 Sep;29(3):1146–1151. doi: 10.1128/iai.29.3.1146-1151.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES